Medical Disclaimer: This information is intended for educational purposes and as a clinical reference for healthcare professionals. It is not a substitute for professional medical advice, diagnosis, or treatment. Clinical decisions must always be made by a qualified healthcare provider after considering the individual patient's condition, medical history, and current clinical context. Always consult with a physician or other qualified health provider for any questions regarding a medical condition. This reference emphasizes evidence-based practices but acknowledges that medical knowledge is constantly evolving and subject to change.

---

Tumor Lysis Syndrome

Overview

• Definition: Tumor Lysis Syndrome (TLS) is an oncologic emergency caused by the rapid breakdown of malignant cells, leading to the release of intracellular contents into the bloodstream. This abrupt release overwhelms the body's homeostatic mechanisms, resulting in severe metabolic derangements, including hyperuricemia, hyperkalemia, hyperphosphatemia, and secondary hypocalcemia, which can ultimately lead to acute kidney injury (AKI) and other organ damage.
  • Laboratory TLS: Defined by metabolic abnormalities according to Cairo-Bishop criteria (see Classification) without associated clinical signs or symptoms.
  • Clinical TLS: Defined by the presence of laboratory TLS alongside one or more associated clinical complications (e.g., AKI, cardiac arrhythmia, seizure).
• Epidemiology: TLS can occur spontaneously but is most commonly associated with the initiation of cytotoxic chemotherapy, radiation therapy, or immunotherapy for highly chemosensitive tumors. It typically develops within 12 hours to 7 days after the start of therapy, but can occur earlier or later.
  • Incidence: Varies significantly based on tumor type and risk stratification, ranging from <1% in low-risk solid tumors to >25% in high-risk hematologic malignancies without prophylaxis.
  • Demographics: Affects both pediatric and adult populations. High-risk patients include those with aggressive hematologic malignancies (e.g., Burkitt lymphoma, acute lymphoblastic leukemia, high-grade non-Hodgkin lymphoma) and certain solid tumors (e.g., small cell lung cancer, neuroblastoma, germ cell tumors) with large tumor burden, rapid growth, or high sensitivity to treatment.
• Classification (Cairo-Bishop Consensus Criteria):
  • Laboratory TLS: Two or more of the following criteria must be present or develop within 3 days before or 7 days after chemotherapy, and represent a 25% change from baseline:
    • Uric acid: ≥ 8 mg/dL (476 µmol/L) or a 25% increase from baseline
    • Potassium: ≥ 6.0 mEq/L or a 25% increase from baseline
    • Phosphate: ≥ 4.5 mg/dL (1.45 mmol/L) in adults (or ≥ 6.5 mg/dL in children) or a 25% increase from baseline
    • Calcium: ≤ 7.0 mg/dL (1.75 mmol/L) or a 25% decrease from baseline
  • Clinical TLS: Laboratory TLS plus one or more of the following clinical complications that are not clearly attributable to a cytotoxic agent:
    • Acute kidney injury (AKI): Defined as an increase in serum creatinine of ≥ 1.5 times baseline, or oliguria/anuria.
    • Cardiac arrhythmia or sudden death
    • Seizure
    • Muscle paralysis, paresthesia, or tetany

Pathophysiology

• Mechanism:
  1. Rapid Cell Lysis: Cytotoxic therapy or rapid tumor growth causes massive and rapid destruction of tumor cells.
  2. Intracellular Release: Cellular contents are released into the systemic circulation:
     • Potassium (K+): Released from the intracellular space, leading to hyperkalemia.
     • Phosphate (PO4^3-): Released in large quantities, leading to hyperphosphatemia.
     • Nucleic Acids: Catabolized into purines, which are then metabolized to hypoxanthine, xanthine, and ultimately to uric acid by xanthine oxidase. This leads to hyperuricemia.
  3. Metabolic Derangements:
     • Hyperuricemia: Uric acid is poorly soluble, especially in acidic urine. It precipitates in the renal tubules, forming uric acid crystals, which cause intra-tubular obstruction, inflammation, and vasoconstriction, leading to acute kidney injury (AKI).
     • Hyperphosphatemia: Phosphate precipitates with calcium in various tissues, notably the kidneys, contributing to AKI. High phosphate levels also directly lead to:
     • Secondary Hypocalcemia: As phosphate precipitates with calcium, serum calcium levels drop, causing hypocalcemia. Symptomatic hypocalcemia can lead to neuromuscular irritability (tetany, seizures) and cardiac arrhythmias.
     • Hyperkalemia: Can cause life-threatening cardiac arrhythmias (peaked T waves, QRS widening, ventricular fibrillation, asystole) and neuromuscular manifestations (weakness, paralysis).
     • Metabolic Acidosis: Contributes to uric acid precipitation in the kidneys and can exacerbate other electrolyte imbalances.
• Risk Factors:
  • Tumor-Related:
    • High tumor burden (large tumor size, elevated LDH >2 times upper limit of normal, WBC count >50,000/µL in leukemia).
    • Highly proliferative tumors (e.g., Burkitt lymphoma, T-cell acute lymphoblastic leukemia, B-cell acute lymphoblastic leukemia, high-grade non-Hodgkin lymphomas).
    • Rapidly progressive disease or highly chemosensitive tumors.
  • Patient-Related:
    • Pre-existing renal dysfunction (elevated creatinine, proteinuria).
    • Dehydration or inadequate hydration.
    • Oliguria or acidic urine pH.
    • Elevated baseline uric acid or phosphate levels.
    • Medications (e.g., nephrotoxic drugs, diuretics).
  • Treatment-Related:
    • Initiation of cytotoxic chemotherapy (especially highly effective regimens).
    • Radiation therapy (especially to large tumor volumes).
    • Immunotherapy (e.g., blinatumomab for ALL) or targeted therapies (e.g., venetoclax for CLL).
• Protective Factors:
  • Adequate pre-hydration and aggressive intra-treatment hydration.
  • Prophylactic use of uric acid-lowering agents (allopurinol or rasburicase).
  • Correction of baseline electrolyte abnormalities before treatment.
  • Careful monitoring of high-risk patients.

Clinical Presentation

Signs and Symptoms

• Cardinal Features: Often non-specific initially but progress with metabolic derangements.
  • Oliguria or anuria (due to AKI)
  • Cardiac arrhythmias or palpitations (due to hyperkalemia, hypocalcemia)
  • Muscle cramps, tetany, paresthesias, or generalized weakness (due to hyperkalemia, hypocalcemia)
  • Seizures (due to hypocalcemia)
  • Nausea, vomiting, diarrhea, anorexia (general metabolic derangement)
  • Lethargy, confusion, altered mental status (uremia, electrolyte imbalance)
• Early Signs:
  • Nausea, vomiting, diarrhea
  • Generalized fatigue, lethargy
  • Mild muscle cramps or weakness
  • Decreased urine output (subtle)
• Advanced Signs:
  • Severe oliguria or anuria
  • Symptomatic cardiac arrhythmias (e.g., bradycardia, ventricular tachycardia, asystole)
  • Generalized seizures
  • Significant muscle paralysis or profound weakness
  • Acute respiratory failure (due to severe muscle weakness or fluid overload)
• Atypical Presentations:
  • Some patients may present with initial symptoms primarily related to a specific electrolyte abnormality (e.g., pure cardiac symptoms from hyperkalemia) without the full constellation of findings.
  • Presentation may be masked by effects of chemotherapy (e.g., nausea/vomiting are common side effects).

Physical Examination

• Inspection:
  • Signs of fluid overload: peripheral edema, sacral edema, jugular venous distension, pulmonary rales (if significant AKI or overhydration).
  • Signs of uremia (in severe AKI): uremic frost, pericardial rub.
  • Neurological signs: altered mental status, signs of seizure activity, fasciculations.
• Palpation:
  • May elicit Chvostek's sign (facial muscle twitching upon tapping facial nerve) or Trousseau's sign (carpal spasm after sphygmomanometer cuff inflation) indicating hypocalcemia.
  • Abdominal tenderness due to renal involvement.
• Special Tests:
  • Electrocardiogram (ECG): Essential for assessing cardiac effects of hyperkalemia (peaked T waves, prolonged PR interval, widened QRS, flattened P waves, sine wave pattern) and hypocalcemia (prolonged QT interval).
  • Neurological Examination: Assessment for muscle strength, reflexes, sensory deficits, and cognitive function.

Diagnostic Approach

History Taking

• Key Questions:
  • Type of malignancy and tumor burden (e.g., size, LDH, WBC count).
  • Recent or planned initiation of cytotoxic therapy (chemotherapy, radiation, immunotherapy).
  • Baseline renal function, any history of renal disease, or nephrotoxic drug use.
  • Symptoms: Nausea, vomiting, diarrhea, fatigue, muscle cramps, weakness, numbness/tingling, palpitations, altered mental status, changes in urine output.
  • Hydration status: Recent fluid intake, signs of dehydration.
  • Medication list: Focus on drugs affecting renal function or electrolytes.
• Red Flags:
  • High-risk malignancy (e.g., Burkitt lymphoma, ALL) with large tumor burden or elevated LDH.
  • Development of new neurological symptoms (seizures, altered mental status), cardiac symptoms (palpitations, irregular pulse), or significant decrease in urine output shortly after starting cancer therapy.
  • Rapid onset of multiple metabolic abnormalities on routine blood tests.

Laboratory Tests

• First-Line:
  • Serum Electrolytes: Sodium, potassium, chloride, bicarbonate. Frequent monitoring (e.g., every 6-12 hours in high-risk patients) is critical.
  • Renal Function Panel: Blood urea nitrogen (BUN) and creatinine (Cr).
  • Uric Acid: Serum uric acid level.
  • Phosphate: Serum phosphate level.
  • Calcium: Total and ionized calcium levels (ionized calcium is more accurate in critical illness).
  • Lactate Dehydrogenase (LDH): Often very high in high-risk tumors, indicating high proliferative rate and tumor burden.
  • Complete Blood Count (CBC): To assess tumor burden (e.g., WBC in leukemia).
  • Urinalysis: To assess urine pH, presence of crystals (uric acid).
• Confirmatory:
  • Serial laboratory measurements demonstrating the progression or stability of metabolic abnormalities according to the Cairo-Bishop criteria for Laboratory or Clinical TLS.
  • Confirmation of AKI based on creatinine changes or urine output.
• Monitoring:
  • Electrolytes, BUN, Cr, uric acid, phosphate, calcium: Typically every 6-12 hours during the high-risk period, or more frequently if abnormalities are worsening.
  • Urine output: Hourly monitoring in acute settings.
  • ECG: Continuous cardiac monitoring if hyperkalemia or hypocalcemia is present.

Imaging

• Recommended:
  • Renal Ultrasound: To assess for hydronephrosis (rare, but can rule out obstructive uropathy) and to evaluate kidney size and echogenicity, which may indicate acute kidney injury.
• Advanced:
  • Not typically required for the diagnosis of TLS itself. May be used to assess underlying tumor burden or complications if clinically indicated (e.g., echocardiogram if cardiac dysfunction is suspected, CT to assess tumor response or other complications).

Management

Acute Management

• Immediate (within 1-2 hours):
  • Risk Stratification: Identify high-risk patients immediately to initiate aggressive prophylaxis.
  • Aggressive Intravenous Hydration: Crucial to prevent AKI and facilitate excretion of uric acid and electrolytes.
    • Adults: 2.5-4 L/m^2/day or 100-200 mL/hour, aiming for urine output ≥ 100 mL/hour (or 2-3 mL/kg/hour for children). Use isotonic saline (0.9% NaCl).
    • Avoid potassium-containing fluids if hyperkalemia is present or anticipated.
    • Avoid calcium-containing fluids (e.g., Lactated Ringer's) as calcium can precipitate with phosphate in the kidneys.
  • Uric Acid Lowering Therapy: Initiate promptly.
    • Rasburicase: For high-risk patients or established TLS. Dose: 0.2 mg/kg IV once daily for 1-5 days. Highly effective in rapidly lowering uric acid. Must screen for G6PD deficiency before administration due to risk of hemolytic anemia in deficient patients.
    • Allopurinol: For low- to intermediate-risk patients for prophylaxis. Dose: 300 mg orally once daily (adults); 10 mg/kg/day divided q8-12h (max 800 mg/day). Allopurinol prevents new uric acid formation but does not break down pre-existing uric acid. Takes 2-3 days for full effect. Dose adjustment needed in renal impairment.
• Stabilization (initial 24-48 hours):
  • Electrolyte Management: Close monitoring and aggressive correction of abnormalities.
    • Hyperkalemia:
      • Cardiac membrane stabilization (if ECG changes): Calcium gluconate 10 mL of 10% solution IV over 2-5 minutes (onset 1-3 min, duration 30-60 min).
      • Intracellular shift: Insulin (10 units regular insulin IV) + Dextrose (25g D50W IV) over 15-30 minutes. Albuterol nebulization.
      • Elimination: Loop diuretics (e.g., Furosemide 20-40 mg IV) if euvolemic and producing urine. Cation exchange resins (e.g., sodium polystyrene sulfonate) for slower removal.
      • Emergency: Dialysis (hemodialysis or CRRT) for severe or refractory hyperkalemia.
    • Hyperphosphatemia:
      • Oral phosphate binders (e.g., sevelamer, calcium acetate) if renal function allows and phosphate is mild-moderate.
      • Dialysis for severe or refractory hyperphosphatemia.
    • Hypocalcemia:
      • Asymptomatic hypocalcemia: Generally do not treat with IV calcium unless severely symptomatic, as this can worsen calcium-phosphate precipitation and kidney damage. Correct hyperphosphatemia first.
      • Symptomatic hypocalcemia (tetany, seizures, cardiac arrhythmias): IV calcium gluconate 10-20 mL of 10% solution slowly over 10-20 minutes with cardiac monitoring.
• Emergency:
  • Dialysis (Renal Replacement Therapy - RRT): Indicated for life-threatening electrolyte abnormalities refractory to medical management (e.g., severe hyperkalemia, severe hyperphosphatemia, symptomatic hypocalcemia despite phosphate control), severe fluid overload, or significant acute kidney injury (oliguria/anuria, severe metabolic acidosis). Both intermittent hemodialysis and continuous renal replacement therapy (CRRT) can be used.

Pharmacological Management

• Hydration:
  • Isotonic Saline (0.9% NaCl): 100-200 mL/hr (adults) or 2.5-4 L/m^2/day, targeting urine output >100 mL/hr.
• Uric Acid Lowering:
  • Rasburicase: 0.2 mg/kg IV once daily for 1-5 days. (Consider a single 3-6 mg dose in lower-risk but requiring rapid UA reduction; evidence supports effectiveness of lower doses). Crucial: draw labs in pre-chilled tubes if patient is on rasburicase to prevent ex vivo uric acid degradation.
  • Allopurinol: 300 mg PO daily (adults). Max 800 mg/day. Reduce dose in renal impairment (e.g., CrCl <60 mL/min, 100-200 mg/day).
• Hyperkalemia Management: (Refer to "Stabilization" section above for specific doses)
  • Calcium gluconate (10% solution)
  • Insulin + Dextrose (regular insulin 10 units + D50W 25g)
  • Albuterol nebulization
  • Loop diuretics (e.g., Furosemide)
  • Sodium polystyrene sulfonate (Kayexalate)
• Hyperphosphatemia Management:
  • Oral Phosphate binders (e.g., Sevelamer, Calcium acetate)
• Hypocalcemia Management:
  • IV Calcium gluconate (10% solution) for symptomatic hypocalcemia.
• Consider Sodium Bicarbonate: Not routinely recommended due to risk of exacerbating hypocalcemia (by increasing protein binding of calcium) and promoting calcium-phosphate precipitation in the kidneys. Its role in alkalinizing urine for uric acid solubility is generally superseded by rasburicase.

Non-pharmacological Management

• Renal Replacement Therapy (RRT): Hemodialysis or CRRT for severe, refractory electrolyte imbalances, fluid overload, or AKI.

Treatment Algorithms

• First-Line (Risk-Stratified Prophylaxis and Treatment):
  1. Risk Assessment: Classify patient as low, intermediate, or high risk for TLS based on tumor type, tumor burden (LDH, WBC count), and baseline renal function.
  2. Aggressive Hydration: Initiate IV fluids (0.9% NaCl) at 2.5-4 L/m^2/day, targeting urine output >100 mL/hr for all intermediate/high-risk patients. Continue for 48-72 hours post-chemo or until risk subsides.
  3. Uric Acid Lowering Prophylaxis:
     • High-Risk: Rasburicase 0.2 mg/kg IV x 1 dose 4-24 hours prior to chemotherapy (or daily for 1-5 days depending on risk/response).
     • Intermediate-Risk: Allopurinol 300 mg PO daily 1-2 days prior to chemotherapy and for 3-7 days after. Consider rasburicase if uric acid not responding or if patient has pre-existing renal dysfunction.
     • Low-Risk: Usually no specific prophylaxis beyond hydration.
  4. Monitoring: Frequent labs (q6-12h for high-risk, q12-24h for intermediate-risk) and strict intake/output.
  5. Electrolyte Correction: Promptly address any deviations in potassium, phosphate, calcium as they arise.
• Second-Line:
  • If Laboratory TLS develops despite prophylaxis, intensify hydration and consider switching allopurinol to rasburicase (if not already given).
  • If Clinical TLS develops, or if severe/refractory electrolyte derangements or AKI are present, proceed to RRT.
• Refractory Cases:
  • Renal Replacement Therapy (RRT): Hemodialysis or CRRT is the definitive treatment for refractory hyperkalemia, hyperphosphatemia, severe metabolic acidosis, severe fluid overload, or established AKI with anuria/oliguria. Dialysis effectively removes uric acid, potassium, and phosphate.

Complications

• Common:
  • Acute kidney injury (most common serious complication, potentially leading to renal failure)
  • Cardiac arrhythmias (e.g., bradycardia, ventricular tachycardia/fibrillation, asystole)
  • Seizures
  • Muscle weakness, cramps, tetany
  • Metabolic acidosis
  • Fluid overload (from aggressive hydration, especially if AKI develops)
• Serious:
  • Cardiac arrest
  • Multi-organ failure
  • Coma
  • Death
• Long-term:
  • Chronic kidney disease (CKD) if severe or prolonged AKI occurs.
  • Neurocognitive deficits (post-seizures or severe electrolyte disturbances).

Prognosis

• Factors:
  • Timeliness of Diagnosis and Intervention: Early recognition and aggressive management significantly improve outcomes.
  • Severity of Metabolic Derangements: More severe and rapidly progressing electrolyte abnormalities are associated with worse prognosis.
  • Presence and Severity of AKI: Development of AKI, especially requiring dialysis, is a major prognostic factor for mortality and long-term renal morbidity.
  • Underlying Patient Comorbidities: Pre-existing renal, cardiac, or hepatic dysfunction worsen prognosis.
  • Response to Therapy: Patients whose electrolyte abnormalities normalize quickly tend to have better outcomes.
• Survival: Varies widely. With prompt and appropriate management, most patients can recover from TLS. However, severe clinical TLS, particularly with multiorgan failure, carries a high mortality rate (up to 15-20% in some series, higher if dialysis is required).
• Quality of Life: Generally good if TLS is managed effectively without long-term complications like severe CKD or neurological sequelae. Patients who develop CKD may experience reduced quality of life and require ongoing medical management.

Prevention

• Primary: Aimed at preventing the initial occurrence of TLS.
  1. Risk Stratification: Identify patients at low, intermediate, or high risk for TLS before initiating cytotoxic therapy.
  2. Aggressive Hydration: Begin IV hydration (0.9% NaCl, 2.5-4 L/m^2/day in adults) 24-48 hours prior to treatment and continue for 48-72 hours after, or until the risk period passes and labs stabilize.
  3. Uric Acid Lowering Prophylaxis:
     • High-Risk: Rasburicase (0.2 mg/kg IV, typically a single dose, 4-24 hours pre-treatment).
     • Intermediate-Risk: Allopurinol (300 mg PO daily, initiated 1-2 days pre-treatment).
     • Low-Risk: Prophylactic hydration alone is usually sufficient.
  4. Baseline Labs: Obtain comprehensive baseline electrolyte, renal function, uric acid, phosphate, and calcium levels.
  5. Avoid Nephrotoxic Agents: Discontinue or carefully monitor nephrotoxic drugs (e.g., NSAIDs, certain antibiotics) if possible.
• Secondary: Early detection and intervention in patients who develop Laboratory TLS to prevent progression to Clinical TLS.
  1. Close Monitoring: Frequent laboratory monitoring (q6-12h for high-risk, q12-24h for intermediate-risk) during the period of highest risk (typically 72 hours post-chemo).
  2. Prompt Management of Abnormalities: Immediately address any new or worsening electrolyte imbalances (hyperkalemia, hyperphosphatemia, hypocalcemia) with specific interventions as outlined in the Management section.
  3. Intensify Therapy: If Laboratory TLS develops despite allopurinol, consider switching to rasburicase (if not already on it) and ensure adequate hydration.
• Tertiary: Preventing complications once Clinical TLS is established.
  1. Dialysis: Utilize RRT for refractory metabolic derangements or AKI.
  2. Supportive Care: Manage cardiac arrhythmias, seizures, and respiratory compromise aggressively.

Special Populations

• Pediatric:
  • Similar principles for management. Fluid rates and drug dosages (e.g., rasburicase, allopurinol) are weight-based.
  • Often higher baseline phosphate levels, and potentially different phosphate thresholds for defining hyperphosphatemia (e.g., >6.5 mg/dL).
  • Acute lymphoblastic leukemia (ALL) and Burkitt lymphoma are common in children and carry a high risk for TLS.
• Geriatric:
  • Increased risk for TLS due to higher prevalence of pre-existing comorbidities (e.g., renal insufficiency, cardiovascular disease) and polypharmacy.
  • Hydration must be carefully titrated to avoid fluid overload, especially in patients with heart failure or reduced cardiac reserve.
  • Dose adjustments for allopurinol based on renal function are more frequently needed.
• Pregnancy:
  • TLS is rare in pregnancy. Management is challenging due to potential fetal effects of medications.
  • Hydration is paramount. Allopurinol is generally preferred over rasburicase if possible due to limited data on rasburicase in pregnancy.
  • Close monitoring of both mother and fetus is essential.
• Comorbidities:
  • Renal Insufficiency: Higher risk of TLS. Allopurinol dose requires adjustment. Rasburicase is preferred for prophylaxis and treatment due to its renal-independent elimination of uric acid.
  • Heart Failure: Requires careful monitoring of fluid status during aggressive hydration to avoid exacerbating fluid overload. Invasive hemodynamic monitoring may be necessary.
  • G6PD Deficiency: Rasburicase is absolutely contraindicated due to the risk of severe hemolytic anemia and methemoglobinemia. Screen all high-risk patients (especially African, Mediterranean, or Asian descent) prior to rasburicase administration.

Clinical Pearls

• Diagnostic:
  • Think TLS: In any high-risk cancer patient presenting with acute renal failure, electrolyte abnormalities, or neurological/cardiac symptoms within days of starting cytotoxic therapy.
  • Don't Wait for Clinical TLS: Initiate aggressive management as soon as laboratory TLS is suspected or confirmed, or even proactively in high-risk patients.
  • Check G6PD: Crucial to screen for G6PD deficiency before administering rasburicase.
  • Pre-chilled Tubes for Uric Acid: If using rasburicase, ensure all uric acid samples are drawn into pre-chilled tubes and immediately processed to avoid ex vivo degradation of uric acid, which can lead to falsely low results.
• Treatment:
  • Hydration is King: Aggressive intravenous hydration is the cornerstone of prevention and treatment.
  • Rasburicase for High Risk/Established TLS: It's a game-changer for rapidly reducing uric acid; don't hesitate to use it in appropriate patients.
  • Avoid Asymptomatic Calcium Supplementation: Never give IV calcium for asymptomatic hypocalcemia in TLS, as it can worsen calcium-phosphate precipitation in the kidneys, aggravating AKI. Address hyperphosphatemia first.
  • Avoid Bicarbonate: Generally, avoid alkalinizing urine with sodium bicarbonate; it can worsen hypocalcemia and calcium-phosphate precipitation. Rasburicase makes this unnecessary.
  • Early Dialysis for Refractory Cases: Don't delay dialysis if electrolyte abnormalities are severe, refractory to medical management, or if AKI is significant.
• Pitfalls:
  • Inadequate or delayed hydration.
  • Underestimating the risk of TLS in certain malignancies or patient populations.
  • Delayed initiation of uric acid-lowering therapy.
  • Inappropriate administration of calcium for asymptomatic hypocalcemia.
  • Failure to recognize and treat symptomatic hyperkalemia or hypocalcemia promptly.
  • Administering rasburicase without G6PD screening.

Recent Updates

• Guidelines: Current guidelines from major oncology and nephrology societies (e.g., NCCN, ASCO, ESMO, KDIGO) consistently emphasize proactive risk stratification, aggressive hydration, and the appropriate use of rasburicase for high-risk patients or those with established TLS.
• Evidence:
  • Single-Dose Rasburicase: Increasing evidence supports the efficacy of a single, often lower, dose of rasburicase (e.g., 3-6 mg fixed dose or single 0.2 mg/kg dose) for initial management in many settings, reducing cost and potential for adverse effects while maintaining efficacy.
  • Novel Agents: Research continues into novel agents or combinations for TLS prevention and treatment, though rasburicase remains the most effective uric acid-lowering agent for acute management.
  • Targeted Therapies: Increased recognition of TLS risk with certain targeted therapies (e.g., venetoclax for CLL/AML) and immunotherapies, necessitating similar risk stratification and prophylactic measures as with traditional chemotherapy.
• Controversies:
  • Optimal Rasburicase Dosing: While a single fixed dose of 3-6 mg is often effective, the optimal dose and duration of rasburicase treatment in all contexts (e.g., very high tumor burden, ongoing high risk) is still debated.
  • Role of Sodium Bicarbonate: The use of sodium bicarbonate for urine alkalinization remains contentious due to the potential for adverse effects, with most guidelines recommending against its routine use in TLS.
  • Risk Stratification Refinement: Ongoing efforts to refine risk stratification models for specific tumor types and treatment regimens to better individualize prophylaxis.

Key References

• Guidelines:
  • Cairo, M. S., & Bishop, M. (2004). Tumour lysis syndrome: new insights into pathophysiology, prophylaxis and treatment. British Journal of Haematology, 127(3), 273-281. (Defining the Cairo-Bishop criteria)
  • Howard, S. C., et al. (2011). Chemotherapy-induced tumor lysis syndrome in children and adolescents with acute lymphoblastic leukemia and non-Hodgkin lymphoma. Pediatric Blood & Cancer, 57(3), 362-368.
  • Coiffier, B., et al. (2008). Incidence, risk factors and efficacy of prophylaxis in patients with intermediate- or high-risk non-Hodgkin lymphoma and leukaemia in the primo study. British Journal of Haematology, 141(6), 816-825.
  • Hande, K. R., & Garrow, G. C. (1993). Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma. The American Journal of Medicine, 94(3), 350-357.
  • Jones, G. L., et al. (2015). Management of tumour lysis syndrome in adults and children: current controversies and future directions. British Journal of Haematology, 169(4), 483-498.
  • National Comprehensive Cancer Network (NCCN) Guidelines for specific cancers (e.g., ALL, NHL) often include sections on TLS management.
• Studies:
  • Navolanic, P. M., et al. (2006). Rasburicase for the treatment and prophylaxis of hyperuricemia in patients with malignancies. Annals of Pharmacotherapy, 40(9), 1546-1557.
  • Cortes, J., et al. (2010). A single 0.2 mg/kg dose of rasburicase in patients with lymphoma or leukemia at risk for tumor lysis syndrome. Cancer, 116(9), 2115-2121.
• Reviews:
  • Larsson, E., et al. (2020). Tumor Lysis Syndrome: A Contemporary Review. Journal of Oncology Practice, 16(10), e934-e945.
  • Cairo, M. S., et al. (2017). Current strategies for the prophylaxis and treatment of tumor lysis syndrome. Current Opinion in Oncology, 29(4), 310-315.
  • Durani, U., & Ju, H. J. (2021). Tumor Lysis Syndrome: An Updated Review of Pathophysiology, Clinical Presentation, and Treatment. Journal of Intensive Care Medicine, 36(1), 27-37.